European Biotechnology Magazine

Finnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected before year-end.

The post

Over the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its autoimmune drug Vyvgart (efgartigimod alfa) in ­diseases such as generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). We caught up with CEO Karen Massey to discuss how she plans to build on this success after joini...

Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.

The post

For CDMOs, flexible upstream platforms can help streamline process ­development while maintaining reproducibility and continuity across scales.

The post Every process is different. Not the platform. appeared fi...

Italy's Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug's clinical studies. The company will ask the agency to lift the hold by screening patients for hidden heart-rhythm disorders, including with genetic tests.

The post